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Abstract
BACKGROUND—The addition of azithromycin to standard regimens for antibiotic prophylaxis 
before cesarean delivery may further reduce the rate of postoperative infection. We evaluated the 
benefits and safety of azithromycin-based extended-spectrum prophylaxis in women undergoing 
nonelective cesarean section.
METHODS—In this trial conducted at 14 centers in the United States, we studied 2013 women 
who had a singleton pregnancy with a gestation of 24 weeks or more and who were undergoing 
cesarean delivery during labor or after membrane rupture. We randomly assigned 1019 to receive 
500 mg of intravenous azithromycin and 994 to receive placebo. All the women were also 
scheduled to receive standard antibiotic prophylaxis. The primary outcome was a composite of 
endometritis, wound infection, or other infection occurring within 6 weeks.
RESULTS—The primary outcome occurred in 62 women (6.1%) who received azithromycin and 
in 119 (12.0%) who received placebo (relative risk, 0.51; 95% confidence interval [CI], 0.38 to 
0.68; P<0.001). There were significant differences between the azithromycin group and the 
placebo group in rates of endometritis (3.8% vs. 6.1%, P = 0.02), wound infection (2.4% vs. 6.6%, 
P<0.001), and serious maternal adverse events (1.5% vs. 2.9%, P = 0.03). There was no significant 
between-group difference in a secondary neonatal composite outcome that included neonatal death 
and serious neonatal complications (14.3% vs. 13.6%, P = 0.63).
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CONCLUSIONS—Among women undergoing nonelective cesarean delivery who were all 
receiving standard antibiotic prophylaxis, extended-spectrum prophylaxis with adjunctive 
azithromycin was more effective than placebo in reducing the risk of postoperative infection. 
(Funded by the Eunice Kennedy Shriver National Institute of Child Health and Human 
Development; C/SOAP ClinicalTrials.gov number, NCT01235546.)
GLOBALLY, PREGNANCY-ASSOCIATED IN-fection is a major cause of maternal death 
and is the fourth most common cause in the United States.1 Maternal infection is also 
associated with a prolonged hospital stay and increased health care costs.2,3 Cesarean 
delivery is the most common major surgical procedure4 and is associated with a rate of 
surgical-site infection (including endometritis and wound infection) that is 5 to 10 times the 
rate for vaginal delivery.5 Despite routine use of antibiotic prophylaxis (commonly, a 
cephalosporin given before skin incision6), infection after cesarean section remains an 
important concern, particularly among women who undergo nonelective procedures (i.e., 
unscheduled cesarean section during labor, after membrane rupture, or for maternal or fetal 
emergencies).6-12 As many as 60 to 70% of all cesarean deliveries are nonelective; 
postoperative infections occur in up to 12% of women undergoing non-elective cesarean 
delivery with standard preincision prophylaxis.13,14
Studies (including a single-center randomized trial) suggest that azithromycin-based 
extended-spectrum prophylaxis — a single dose of azithromycin plus standard 
cephalosporin prophylaxis — may result in a lower risk of infection after cesarean section 
than standard prophylaxis alone.15 It has been thought that the efficacy of such prophylaxis 
was due to coverage for ureaplasma species, which are commonly associated with infections 
after cesarean section.16-21 We performed this study to assess whether the addition of 
azithromycin to standard antibiotic prophylaxis before skin incision would reduce the 
incidence of infection after cesarean section without increasing the risk of other adverse 
maternal and perinatal outcomes.
METHODS
TRIAL DESIGN AND OVERSIGHT
The Cesarean Section Optimal Antibiotic Prophylaxis (C/SOAP) trial was a double-blind, 
pragmatic, randomized clinical trial conducted at 14 hospitals in the United States. The 
institutional review board at each study site approved the trial protocol, which is available 
with the full text of this article at NEJM.org. Written informed consent was obtained from 
all the patients. Funding was provided by the Eunice Kennedy Shriver National Institute of 
Child Health and Human Development. Pfizer donated the azithromycin that was used in the 
trial but did not participate in the design, conduct, or reporting of the trial. An independent 
data and safety monitoring board oversaw the trial. The first two authors take responsibility 
for the accuracy and completeness of the reporting and the fidelity of the report to the trial 
protocol.
TRIAL DESIGN
Women with a singleton pregnancy with a gestation of 24 weeks or more who were 
undergoing nonelective cesarean delivery during labor or after membrane rupture were 
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eligible. Labor was defined as regular contractions with cervical dilation of 4 cm or more or 
with documented cervical change of at least 1 cm of dilation or at least 50% effacement. 
Women with membrane rupture for at least 4 hours were eligible, regardless of whether 
labor had started. Most women underwent the consent procedure at admission for delivery 
and were rescreened to confirm eligibility after the decision was made to proceed to 
cesarean delivery. Gestational age was estimated in accordance with the guidelines of the 
American College of Obstetricians and Gynecologists.22
Exclusion criteria were an inability to provide consent, a known allergy to azithromycin, 
subsequent vaginal delivery, azithromycin use within 7 days before randomization, 
chorioamnionitis or other infection requiring postpartum antibiotic therapy (although 
patients receiving antibiotics for group B streptococcus were eligible), and fetal death or 
known major congenital anomaly. We also excluded patients who had substantial liver 
disease (cirrhosis or an aminotransferase level at least three times the upper limit of the 
normal range), a serum creatinine level of more than 2.0 mg per deciliter (177 μmol per liter) 
or the need for dialysis, diarrhea at the time of planned randomization, cardiomyopathy or 
pulmonary edema, maternal structural heart disease, arrhythmias, use of medications known 
to prolong the QT interval, or known substantial electrolyte abnormalities, such as 
hypokalemia, hypocalcemia, or hypomagnesemia.
All the women were to receive standard prophylaxis (cefazolin) according to the protocol at 
each trial center. Patients who were allergic to cephalosporin or penicillin received the local 
alternative medication (clindamycin alone or clindamycin plus gentamicin). Antibiotic 
prophylaxis was administered before surgical incision or as soon as possible thereafter.
INTERVENTIONS
Patients were randomly assigned to receive either azithromycin (at a dose of 500 mg in 250 
ml of saline) or an identical-appearing saline placebo. Clinical and research staff members 
other than the investigational pharmacist were unaware of treatment assignments. The 
computer-generated block-designed randomization plan was produced by the data 
coordinating center and was stratified according to site. Only the investigational pharmacists 
who prepared the study drug had access to the randomization algorithm through a dedicated 
password-protected website.
The 250-ml bags containing the azithromycin or placebo were sequentially numbered and 
kept in a secure refrigerator (7-day shelf life), which allowed for rapid administration after 
randomization. (Expired study bags were discarded without recycling the randomization 
sequence.) Study staff members retrieved the next sequentially numbered study drug bag up 
to 1 hour before incision and typically once the decision was made to proceed to cesarean 
section. At the time that the study infusion was connected, the patient was considered to 
have undergone randomization. Study medication was infused over a period of 1 hour, 
according to Food and Drug Administration guidelines for azithromycin.
Cesarean procedures and care at each center followed providers’ usual practices. Trial 
outcomes and other data were abstracted by certified research staff.
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TRIAL OUTCOMES
The primary outcome was a composite of endometritis, wound infection, or other infections 
(abdominopelvic abscess, maternal sepsis, pelvic septic thrombophlebitis, pyelonephritis, 
pneumonia, or meningitis) occurring up to 6 weeks after surgery. Endometritis was defined 
as the presence of at least two of the following signs with no other recognized cause: fever 
(temperature of at least 38°C [100.4°F]), abdominal pain, uterine tenderness, or purulent 
drainage from the uterus. Wound infection was defined as the presence of either superficial 
or deep incisional surgical-site infection characterized by cellulitis or erythema and 
induration around the incision or purulent discharge from the incision site with or without 
fever and included necrotizing fasciitis. Wound hematoma, seroma, or breakdown alone in 
the absence of the preceding signs did not constitute infection. Diagnosis of abdominal or 
pelvic abscess required radiologic or surgical confirmation. Detailed trial criteria consistent 
with the recommendations of the National Healthcare Safety Network of the Centers for 
Disease Control and Prevention for surgical site infections are provided in the 
Supplementary Appendix, available at NEJM.org.23
Criteria for other infections, which included a clinical diagnosis leading to therapy with 
antibiotics and additional criteria, are provided in the Supplementary Appendix. Primary 
outcomes were centrally adjudicated by investigators who were unaware of treatment 
assignments.
A major secondary neonatal outcome was a composite of death, suspected or confirmed 
sepsis, or other complications, including the respiratory distress syndrome, necrotizing 
enterocolitis, periventricular leukomalacia, grade III or higher intraventricular hemorrhage, 
the systemic inflammatory response syndrome, and bronchopulmonary dysplasia. Other 
secondary outcomes that were specified in the statistical analysis plan included a neonatal 
safety composite (death, allergic reaction, or transfer to a long-term care facility), a maternal 
safety composite outcome (defined below as maternal serious adverse events), and infection 
with resistant organisms.
Other secondary maternal and neonatal outcomes that were specified in the protocol are 
listed in Table S1 in the Supplementary Appendix. Among such outcomes were specific 
maternal postoperative infections, maternal fever, unscheduled visits and readmissions, 
neonatal complications, and length of hospital stay.
Neonatal serious adverse events included the neonatal safety composite, grade III or higher 
intraventricular hemorrhage, sepsis, and other reported serious events. Maternal serious 
adverse events (maternal safety composite outcome) included death, suspected allergic 
reactions (including anaphylaxis or generalized skin rash), any serious adverse event leading 
to the discontinuation of a study medication or suspected to be due to the medication, and 
any other reported serious adverse complication, including pulmonary embolism, admission 
to an intensive care unit (ICU), and cardiac events.
OUTCOME ASCERTAINMENT AND FOLLOW-UP
Trained and certified research staff members who were unaware of treatment assignments 
ascertained maternal and infant outcomes by reviewing medical records from the delivery 
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hospitalization, from visits to a postpartum clinic or emergency department, and from 
hospital admissions. Patients were scheduled for a 6-week postpartum visit (or were 
contacted by telephone) to ascertain maternal and infant medical events and visits and were 
contacted by telephone at 3 months to identify infant deaths and adverse events. Medical 
records (including those at other health facilities) were required to verify study outcomes.
STATISTICAL ANALYSIS
We determined that a sample size of 2000 patients would provide a power of 80% to detect a 
33% relative reduction in the primary outcome from a baseline risk of 12% or a 40% relative 
reduction from a baseline risk of 8%, at a two-sided alpha level of 0.05. We also calculated 
that this sample size would provide a power of 80% or more to assess a 30% relative 
reduction in the composite neonatal outcome, assuming a baseline risk of 16%.14
All analyses were performed according to the intention-to-treat principle. We used the chi-
square test or Fisher's exact test to analyze categorical variables and Student's t-test for 
continuous variables. Relative risks and 95% confidence intervals were calculated for 
outcomes. In secondary analyses, we adjusted for characteristics that were not balanced at 
randomization using logistic-regression models for the primary outcome. Tests of interaction 
in multivariable logistic-regression models were used to test the homogeneity of the 
treatment effect on the primary outcome across subgroups in four prespecified analyses, 
according to trial site, body-mass index (the weight in kilograms divided by the square of the 
height in meters) of less than 30 versus 30 or more, membrane rupture before randomization 
versus after randomization, and initiation of study medication before versus after skin 
incision. We calculated the number of patients who would need to be treated to prevent one 
primary outcome event and 95% confidence intervals.
We performed one planned interim analysis of the primary outcome using O'Brien–Fleming 
boundaries; the final analysis was evaluated at a 0.048 level of significance. All secondary 
outcomes were evaluated at a 0.05 level of significance.
RESULTS
CHARACTERISTICS OF THE PATIENTS
Of 17,790 women who were screened at the 14 clinical sites from April 2011 through 
November 2014, a total of 1019 were randomly assigned to the azithromycin group and 994 
to the placebo group (Fig. 1). The characteristics of the patients at baseline were similar in 
the two groups, except that smoking was slightly less prevalent in the azithromycin group 
(Table 1). The specific characteristics related to the cesarean delivery, including indications 
for cesarean delivery, receipt of standard prophylaxis, timing of receipt of study medication, 
and type of surgical skin preparation, were similar in the two groups (Table 2). More than 
99% of the patients in each group received the standard antibiotic prophylaxis. Azithromycin 
or placebo was administered before incision in 88% of the women in each group. Maternal 
and neonatal outcome data were available for all the patients at the time of hospital 
discharge. Postpartum follow-up within 6 weeks was available for 1961 of the 2013 women 
(97.4%) who underwent randomization (Fig. 1).
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PRIMARY OUTCOME
The primary composite outcome occurred in 62 women (6.1%) who received azithromycin 
and in 119 (12.0%) who received placebo (relative risk, 0.51; 95% confidence interval [CI], 
0.38 to 0.68; P<0.001) (Table 3). The use of azithromycin was associated with significantly 
lower rates of endometritis (3.8% vs. 6.1%; relative risk, 0.62; 95% CI, 0.42 to 0.92; P = 
0.02) and wound infections (2.4% vs. 6.6%; relative risk, 0.35; 95% CI, 0.22 to 0.56; 
P<0.001). The risks of other infections were low and did not differ significantly between 
groups. The number of patients who would need to be treated to prevent one study outcome 
was 17 (95% CI, 12 to 30) for the primary outcome, 43 (95% CI, 24 to 245) for 
endometritis, and 24 (95% CI, 17 to 41) for wound infections. The results were similar after 
planned adjustment for smoking with respect to the primary outcome (adjusted odds ratio, 
0.48; 95% CI, 0.35 to 0.66), endometritis (adjusted odds ratio, 0.61; 95% CI, 0.40 to 0.91), 
and wound infections (adjusted odds ratio, 0.34; 95% CI, 0.21 to 0.55). Results from 
survival analyses were also similar to the findings in the primary analysis (Table S2 and 
Figs. S1 through S4 in the Supplementary Appendix).
Heterogeneity of the effect of adjunctive azithromycin was not detected in prespecified 
subgroups, according to study site, obesity status, membrane status at randomization, and 
timing of medication administration (Table S3 in the Supplementary Appendix). A 
significant interaction was detected in a post hoc analysis of skin-closure methods (P = 
0.02), which suggested a greater reduction in infections for women receiving staples than for 
those receiving sutures. No heterogeneity in treatment effect was detected in other post hoc 
subgroup analyses, including vaginal preparation, group B streptococcal status, diabetes 
status, and preterm delivery.
SECONDARY NEONATAL AND MATERNAL OUTCOMES
The composite neonatal outcome of death or complications occurred in 146 infants (14.3%) 
in the azithromycin group and in 135 (13.6%) in the placebo group (relative risk, 1.05; 95% 
CI, 0.85 to 1.31; P = 0.63) (Table 4). There was one neonatal death in the placebo group, 
which occurred 5 days after birth as a result of extreme prematurity, and three deaths in the 
azithromycin group, which occurred at 15 days from fulminant herpes simplex virus, at 42 
days from uncertain cause, and at 72 days from the sudden infant death syndrome. The 
frequencies of other neonatal outcomes, including neonatal ICU admission or hospitalization 
after discharge, were not significantly different between groups. Other maternal outcomes, 
including rates of postpartum fever, treatment with antibiotics, and need for readmission or 
unscheduled visits for any reason or specifically for infection, were significantly less 
common in the azithromycin group (Table 4).
ADVERSE EVENTS
Maternal serious adverse events were less common in the azithromycin group than in the 
placebo group (1.5% vs. 2.9%, P = 0.03); no significant between-group difference was 
observed in the rates of neonatal serious adverse events, including the safety composite 
outcome (Table 4). Other maternal or neonatal adverse events did not differ significantly 
between groups (Tables S4 and S5 in the Supplementary Appendix).
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BACTERIAL CULTURES AND ANTIMICROBIAL RESISTANCE
We examined results of all clinical maternal postpartum cultures in those with wound 
infections (Table S6 in the Supplementary Appendix). Fifty women (2.5%) had cultures that 
were positive for at least one bacterial organism, most commonly gram-negative bacilli and 
staphylococcus and enterococcus species. The azithromycin group had a significantly lower 
prevalence than the placebo group with respect to positive cultures (1.4% vs. 3.6%, P = 
0.001) and bacteria resistant to at least one antibiotic (1.0% vs. 2.4%, P = 0.01). Bacteria 
resistant to azithromycin were identified in three wound cultures in the azithromycin group 
and four in the placebo group. Overall, 19 newborns (0.9%) had positive culture results 
(mainly in blood samples), with no significant between-group difference in the prevalence (8 
newborns [0.8%] in the azithromycin group and 11 [1.1%] in the placebo group [P = 0.50]) 
or in the prevalence of bacteria resistant to at least one antibiotic (0.5% vs. 0.8%, P = 0.42).
SENSITIVITY ANALYSES
We conducted sensitivity analyses that excluded patients with protocol violations or were 
restricted to women with complete postpartum follow-up data. In these analyses, the results 
were similar to those in the primary analyses (Tables S7 and S8 in the Supplementary 
Appendix).
DISCUSSION
In this large, multicenter, randomized trial, we found that the addition of azithromycin to 
standard antibiotic prophylaxis significantly reduced the frequency of infection after 
nonelective cesarean section. The risks of serious adverse maternal events and several other 
maternal outcomes, including readmissions, were lower in the azithromycin group than in 
the placebo group, and the risks of adverse neonatal outcomes were not increased in this 
group. The number of eligible women who would need to be treated to prevent one study 
outcome was 17 for the primary outcome, 43 for endometritis, and 24 for wound infections. 
In addition, the benefit of the intervention did not appear to vary significantly according to 
prespecified subgroup, including clinical site and timing of administration of the medication 
in relation to skin incision.
Our findings are consistent with those of previous studies supporting a lower risk of 
infection after cesarean section with the use of prophylactic extended-spectrum coverage 
than with standard antibiotic prophylaxis. In some reports, fewer infections were reported 
with the addition of metronidazole, which covers anaerobes, than with standard 
prophylaxis.24-28 We focused on azithromycin because it covers ureaplasma organisms, 
which are more commonly associated with infections after cesarean section than anaerobes 
when specific cultures are performed, and because it has been associated with reduced risks 
of both wound infections and endometritis.15,24-26 A single-center randomized trial 
involving 597 women and subsequent observational studies from the same center indicated 
that women who received azithromycin-based extended-spectrum antibiotic prophylaxis 
administered after umbilical-cord clamping had a rate of postoperative infection that was at 
least 30% lower than did women receiving standard prophylaxis; women in the azithromycin 
group also had a shorter hospital stay.24-26 Contrary to previous studies in which 
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prophylactic extended-spectrum antibiotics were administered after skin incision and 
umbilical-cord clamping, we tested a preincision approach. The vast majority of patients 
received antibiotics before incision, with demonstrated maternal benefits and no evidence of 
neonatal harm.
A limitation of our study is the exclusion of women undergoing a scheduled cesarean section 
and those with intrapartum chorioamnionitis. These exclusions limit the generalizability of 
our findings in these two groups. Previous studies of azithromycin-based extended 
prophylaxis have suggested potential benefits for these two groups of women,22-24 but 
further investigation is warranted to assess efficacy and cost-effectiveness. Such factors are 
important, because women who have a scheduled cesarean delivery have a low risk of 
infection, and those with a diagnosis of chorioamnionitis are treated with broad-spectrum 
antibiotics after cesarean section. The mechanism by which azithromycin reduces the rate of 
infection after cesarean section remains unclear. Specific tests for the presence of 
ureaplasma or mycoplasma species are not routinely performed in practice and were not 
available for this study population. The available culture results suggest that the beneficial 
effect of azithromycin probably extends beyond coverage of ureaplasma organisms.
The selection of resistant organisms is a potential concern regarding azithromycin-based 
prophylaxis. However, it is unlikely that the single dose of antibiotic would significantly 
increase resistance. Our findings from clinical maternal cultures are reassuring, but ongoing 
monitoring for changes in resistance profiles is needed. We excluded women with a history 
of arrhythmia or cardiomyopathy, given a previous observational study reporting an 
association between multiple oral doses of azithromycin over a period of at least 5 days and 
the risk of cardiac death in a nonpregnant, older patient cohort with underlying coexisting 
conditions.29 Our data did not show any safety signal involving cardiac events or maternal 
death with the single intravenous dose of azithromycin; this is consistent with reassuring 
findings subsequently reported in a general population of young and middle-aged healthy 
adults.30
Standard antibiotic prophylaxis has been shown to reduce rates of surgical-site infection 
after cesarean section, along with rates of serious maternal complications and death.11 Our 
findings indicate that extended-spectrum prophylaxis with adjunctive azithromycin for 
cesarean delivery in women at increased risk for infection safely reduces the rates of 
infection and maternal use of health care resources without increasing the risk of neonatal 
adverse outcomes.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Enrollment and Outcomes
In the azithromycin group, 1018 patients received the assigned drug, but data were missing 
on the timing of administration in 9. In the placebo group, 992 patients received the assigned 
saline infusion, but the timing was not documented in 11.
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Table 1
Characteristics of the Patients at Baseline.*
Characteristic Azithromycin (N = 1019) Placebo (N = 994)
Age — yr 28.2±6.1 28.4±6.5
Race or ethnic group — no. (%)†
    Non-Hispanic black 351 (34.4) 341 (34.3)
    Hispanic 203 (19.9) 208 (20.9)
    Non-Hispanic white 356 (34.9) 342 (34.4)
    Other 109 (10.7) 103 (10.4)
Body-mass index‡
    Mean 35.3±7.7 35.5±7.9
    Category — no. (%)
        <18.5 1 (01) 1 (01)
        18.5 to <25 53 (5.2) 43 (4.3)
        25 to <30 217 (21.3) 221 (22.2)
        30 to <40 503 (49.4) 478 (48.1)
        ≥40 243 (23.8) 249 (25.1)
        Missing data 2 (0.2) 2 (0.2)
Private insurance — no./total no. (%)† 317/1008 (31.4) 312/983 (31.7)
Previous pregnancy — no. (%)
    Any 552 (54.2) 560 (56.3)
    ≥20 wk of gestation 416 (40.8) 402 (40.4)
Diabetes mellitus — no. (%)
    Any 142 (13.9) 146 (14.7)
    Gestational only 99 (9.7) 106 (10.7)
Chronic hypertension — no. (%) 51 (5.0) 54 (5.4)
Smoking during pregnancy — no. (%) 97 (9.5) 122 (12.3)
Alcohol use during pregnancy — no. (%) 41 (4.0) 47 (4.7)
Use of illegal drugs during pregnancy — no. (%) 35 (3.4) 28 (2.8)
Positive for group B streptococcus — no. (%) 249 (24.4) 266 (26.8)
Gestational age
    At randomization — wk 38.9±2.3 39.0±2.3
    <37 wk at delivery — no. (%) 112 (11.0) 114 (11.5)
*
Plus-minus values are means ±SD. There were no significant differences between the groups except for smoking during pregnancy (P=0.047). 
Percentages may not total 100 because of rounding.
†
Race or ethnic group was self-reported.
‡
The body-mass index is the weight in kilograms divided by the square of the height in meters.
N Engl J Med. Author manuscript; available in PMC 2017 March 29.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Tita et al. Page 13
Table 2
Characteristics of Cesarean Procedures.
Characteristic Azithromycin (N = 1019) Placebo (N = 994) P Value
no./total no. (%)
Primary indication for cesarean delivery* 0.97
    Failure to progress 360/1019 (35.3) 342/993 (34.4)
    Nonreassuring fetal heart tones 268/1019 (26.3) 258/993 (26.0)
    Failed induction 105/1019 (10.3) 103/993 (10.4)
    Elective repeat procedure meeting study criteria 94/1019 (9.2) 95/993 (9.6)
    Abnormal presentation 59/1019 (5.8) 67/993 (6.7)
    Other reason 133/1019 (13.1) 128/993 (12.9)
Receipt of standard antibiotic prophylaxis 1017/1019 (99.8) 990/994 (99.6) 0.45
Timing of study-drug administration
    Before skin incision† 884/1009 (87.6) 860/981 (87.7) 0.97
        0 to 60 min before 833/1009 (82.6) 815/981 (83.1)
        >60 min before 51/1009 (5.1) 45/981 (4.6)
    After incision 125/1009 (12.4) 121/981 (12.3)
Membrane rupture before skin incision 889/1012 (87.8) 868/987 (87.9) 0.95
Skin-incision type 0.10
    Pfannenstiel 987/1019 (96.9) 947/992 (95.5)
    Vertical 32/1019 (3.1) 45/992 (4.5)
Closure method 0.91
    Staples 415/1019 (40.7) 411/992 (41.4)
    Suture 593/1019 (58.2) 569/992 (57.4)
    Dermabond 11/1019 (1.1) 12/992 (1.2)
Uterine incision 0.99
    Low transverse 975/1019 (95.7) 949/992 (95.7)
    Other 44/1019 (4.3) 43/992 (4.3)
Skin preparation
    Chlorhexidine 369/1019 (36.2) 364/994 (36.6) 0.78
    Chlorhexidine–alcohol 340/1019 (33.4) 316/994 (31.8)
    Chlorhexidine–alcohol plus iodine 218/1019 (21.4) 213/994 (21.4)
    Iodine–alcohol 92/1019 (9.0) 101/994 (10.2)
Vaginal preparation
    Any 265/1019 (26.0) 258/994 (26.0) 0.98
    Type
        Iodine 254/1019 (24.9) 243/994 (24.4) 0.68
        Chlorhexidine 11/1019 (1.1) 15/994 (1.5)
        None 754/1019 (74.0) 736/994 (74.0)
*One patient in the placebo group did not have a primary indication for cesarean delivery.
N Engl J Med. Author manuscript; available in PMC 2017 March 29.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Tita et al. Page 14
†
The P value for this category is for the between-group comparison for administration of the study drug before the incision versus administration 
after the incision.
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Table 3
Primary Composite Outcome and Its Components.*
Outcome Azithromycin (N = 1019) Placebo (N = 994) Relative Risk (95% CI) P Value
no. (%)
Primary composite outcome 62 (6.1) 119 (12.0) 0.51 (0.38–0.68) <0.001
Endometritis 39 (3.8) 61 (6.1) 0.62 (0.42–0.92) 0.02
Wound infection 24 (2.4) 66 (6.6) 0.35 (0.22–0.56) <0.001
    Necrotizing fasciitis 0 4 (0.4) NA 0.06
    Deep wound infection 6 (0.6) 8 (0.8) 0.73 (0.25–2.10) 0.56
Other infection 3 (0.3) 6 (0.6) 0.49 (0.12–1.94) 0.34
    Abdominal or pelvic abscess 0 4 (0.4) NA 0.06
    Septic pelvic thrombophlebitis 0 0 NA NA
    Maternal sepsis 2 (0.2) 1 (0.1) 1.95 (0.18–21.5) >0.99
    Pyelonephritis 1 (01) 0 NA >0.99
    Pneumonia 1 (0.1) 2 (0.2) 0.49 (0.04–5.37) 0.62
    Meningitis 0 0 NA NA
*NA denotes not applicable.
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Table 4
Secondary Neonatal and Maternal Outcomes.*
Outcome Azithromycin (N = 1019) Placebo (N = 994) Relative Risk (95% CI) P Value
no. of patients (%)
Neonatal
Composite neonatal outcome 146 (14.3) 135 (13.6) 1.05 (0.85–1.31) 0.63
    Sepsis
        Suspected 120 (11.8) 124 (12.5) 0.94 (0.75–1.19) 0.63
        Confirmed 1 (01) 1 (01) 0.98 (0.06–15.6) >0.99
Death
    Within 3 mo 3 (0.3) 1 (01) 2.93 (0.30–28.1) 0.62
    Within 28 days 1 (01) 1 (01) 0.98 (0.06–15.6) >0.99
Composite neonatal complications 45 (4.4) 34 (3.4) 1.29 (0.83–2.00) 0.25
    Respiratory distress syndrome 42 (4.1) 33 (3.3) 1.24 (0.79–1.94) 0.34
    Necrotizing enterocolitis 1 (0.1) 0 NA >0.99
    Periventricular leukomalacia 0 0 NA NA
    Intraventricular hemorrhage of grade III or more 1 (0.1) 2 (0.2) 0.49 (0.04–5.37) 0.62
    Bronchopulmonary dysplasia 4 (0.4) 3 (0.3) 1.30 (0.29–5.80) >0.99
    Systemic inflammatory response syndrome 0 1 (0.1) NA 0.493
NICU admission 171 (16.8) 169 (17.0) 0.99 (0.81–1.20) 0.89
Readmission or unscheduled visit 170 (16.7) 140 (14.1) 1.18 (0.96–1.46) 0.11
Readmission 39 (3.8) 43 (4.3) 0.88 (0.58–1.35) 0.57
Maternal
Postpartum fever 51 (5.0) 81 (8.1) 0.61 (0.44–0.86) 0.004
Any postpartum readmission or unscheduled visit 83 (8.1) 123 (12.4) 0.66 (0.51–0.86) 0.002
    Clinic visit 32 (3.1) 53 (5.3) 0.59 (0.38–0.91) 0.02
    Emergency department visit 54 (5.3) 84 (8.5) 0.63 (0.45–0.87) 0.005
    Readmission 27 (2.6) 49 (4.9) 0.54 (0.34–0.85) 0.007
    Because of infection 23 (2.3) 62 (6.2) 0.36 (0.23–0.58) <0.001
Postpartum use of antibiotics 126 (12.4) 166 (16.7) 0.74 (0.60–0.92) 0.006
Composite serious adverse events†
Neonatal serious adverse events
    Any 7 (0.7) 5 (0.5) 1.37 (0.43–4.29) 0.77
    Safety composite‡ 3 (0.3) 1 (01) 2.93 (0.30–28.1) 0.62
All maternal serious adverse events§ 15 (1.5) 29 (2.9) 0.50 (0.27–0.94) 0.03
*NA denotes not applicable, and NICU neonatal intensive care unit.
†
Details about serious adverse events are provided in Table S4 in the Supplementary Appendix.
‡
This category is a composite of perinatal death, perinatal allergic reaction, and neonatal transfer to a chronic care facility.
§
This category is the same as the maternal safety composite.
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